Lifemd, Inc. · NASDAQ:LFMD
Lifemd — Immudyne — Investor Presentation (April 2013)
17 slides from Lifemd's investor presentation, Apr 18, 2013
Slide 1: Immudyne Corporate Presentation
IMMUDYNE Corporate Presentation April 18, 2013
Slide 2: Disclaimer
Disclaimer This Presentation includes and is based, inter alia, on forward - looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. These statements and this Presentation are based on current expectations, estimates and projections,
Slide 3: ImmuDyne is a Health & Wellness Lifestyle Company
ImmuDyne (OTCQB: IMMD) ImmuDyne is a Health & Wellness Lifestyle Company Immudyne develops products to help people feel better, look better, and experience a wellness lifestyle through an empowered immune system Copyright ©2013. All rights reserved. Immudyne ,Inc..
Slide 4: ImmuDyne Overview
ImmuDyne Overview ImmuDyne has offices in Mt. Kisco , NY – Executive Carlsbad, CA – Sales & Marketing Florence, KY – Manufacturing ▪ State of the art facility ▪ cGMP compliant
Slide 5: Product Overview
Product Overview Since 1990, Immudyne has been providing value to patients and consumers with our extensively researched, patent - protected yeast beta 1,3/1,6 - D - glucan supplement, Puracere ™ ( fka MacroForce ) US Patents: 5,519,009 │ 5,397,773 │ 5,576,015 │ 5,702,719 │ 5,705,184 3 new patents a
Slide 6: Product Overview continued
Product Overview continued Yeast b eta 1/3, 1/6 - D glucan Primes the Innate I mmune Response ▪ Activates neutrophils, B - lymphocytes, T - helper cells, NK1 cells, and macrophages to destroy harmful pathogens such as bacteria, fungi, protozoan ▪ Assists in the natural detoxification process ▪ Reduc
Slide 7: Month Plan Q2 2013 - Q3 2014
15 - Month Plan Q2 2013 - Q3 2014
Slide 8: Strategic Imperatives & Tactics
Strategic Imperatives & Tactics ▪ Redefine corporate identity and launch new corporate site ▪ Launch new brand identity for flagship yeast beta 1/3, 1/6 - D glucan , PuraCere ™ ▪ Expand product portfolio through the creation of new, patent - protected PuraCere ™ and Nayad ® based products lines ▪ Ex
Slide 9: Key US Markets – Blue Oceans
Key US Markets – Blue Oceans • Post Alcohol Consumption (PAC) – Over 120 million Americans are frequent drinkers – Approximately 1/3 of this audience is binge drinkers – A hangover is not only the results of dehydration as alcohol is a toxin and immunosuppressant August 2013: beta launch IMMD PAC pr
Slide 10: Key US Markets continued
Key US Markets continued • Dietary Supplements (DSP) – Approximate $15B US DSP Market will significantly increase over the next several years – Many Americans are ‘over - nourished’ and many multivitamins are adding nutrients not needed by the American body – IMMD DSP strengthens the innate immune s
Slide 11: Cumulative Sales Forecast
15 - Month Cumulative Sales Forecast Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Sales in MM $0.35 $1.00 $5.10 $10.70 $18.00 $- $2.00 $4.00 $6.00 $8.00 $10.00 $12.00 $14.00 $16.00 $18.00 $20.00 $18.0 MM $Millions Total Cumulative Sales Q3 2013 – Q3 2014 $1.0 MM $5.1 MM $10.7 MM $0.35 MM These statements
Slide 12: Thank you for your time
Thank you for your time For further information, please contact: Immudyne , Inc. Mark McLaughlin President & CEO +1 - 914 - 714 - 8901 MarkMcL@immudyne.com OTCQB: IMMD Immudyne, MacroForce , and Nayad are registered trademarks of Immudyne , Inc. PuraCere is a trademark of Immudyne , Inc. Content © 2
Slide 13: Addendum: Clinical Data
Addendum Clinical Data IMMUDYNE
Slide 14: Flagship Products: PuraCere
Flagship Products: PuraCere ™ ▪ PuraCere primes the innate immune response to defend against the underlying cause of many chronic diseases, acute conditions, and the aging process 2 ▪ In a clinical study PuraCere improved overall well - being and increased WBC, hemoglobin, and platelet counts in pat
Slide 15: PuraCere Clinical Data: Improvement of Survival in Terminal Cancer Patients
PuraCere ™ Clinical Data Indicated an Improvement of Survival in Terminal Cancer Patients 0% 20% 40% 60% 80% 100% Day 1 Month 3 Month 6 Effect on Survival in Terminal Patients PuraCere Control n=45 n=54 • In a clinical trial, 65% of patients who receive PuraCere survived more than 3 months • 43% sur
Slide 16: PuraCere Clinical Data: Decrease in Incidence of Relapse after Cancer Surgery
PuraCere ™ Clinical Data Indicated a Decrease in the Incidence of Relapse after Cancer Surgery 10 13 16 19 22 25 28 Month 3 Month 6 Month 9 Month 12 Month 15 Month 20 Incidence of Relapse Post Surgery in Stage 2 Cancer Patients PuraCere Control n =23 n=26 22% of control relapsed by M15 NO RELAPSE 20
Slide 17: Proprietary Skin Care Product: Nayad
Proprietary Skin Care Product: Nayad ® ▪ Nayad ® contains IMMD yeast beta - 1,3/1,6 - D - glucan ▪ Nayad naturally connects with and activates Langerhans cells ▪ Langerhans cells are the immune cells of the skin ▪ Activated Langerhans cells heal microscopic wounds, fight against infection, and count